Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, October 23, 2026

Back to today

From X

@convequity

Convequity on X

Our least-favoured bet on next-generation nuclear: light-water SMRs. Smaller does not automatically mean cheaper. A 50–300 MW small modular reactor produces far less power than a 1 GW plant, but containment, site infrastructure and other costs may not shrink proportionately. Factory production and simpler safety systems can help, but those savings must outweigh the loss of scale. The result could be a higher cost per installed kilowatt, not a lower one. Advanced alternatives offer higher temperatures and more industrial uses. But we think many face a bigger obstacle than licensing: securing enough fuel. To understand the investment trade-offs, separate two questions: what cools the reactor, and what fuels it? Light water → Proven technology, established fuel supply. Uses ordinary water and fuel typically enriched below 5% uranium-235. Runs at around 300°C under pressure, producing electricity and lower-temperature heat. Its advantage is maturity; its limitation is that it cannot directly supply the hottest industrial processes. Shrinking it does not necessarily improve its economics. Sodium → Higher temperatures without high pressure. Transfers heat efficiently and operates near atmospheric pressure, reducing the need for heavy pressure-containing equipment. The catch: sodium burns in air and reacts violently with water, requiring strict separation and additional safeguards. Helium → High-temperature heat without a chemically reactive coolant. Can reach roughly 750°C or more, supporting more efficient electricity generation and industrial heat. Helium does not burn or react chemically, but the system operates under pressure and must stay leak-tight. Leading designs also require specialised TRISO fuel. Fluoride salts → High-temperature heat at low pressure, without sodium’s fire risk. The challenges are corrosion, suitable materials and preventing the salt from freezing. Some designs, such as Kairos Power’s, use salt to cool solid TRISO fuel. Others dissolve the fuel in the salt itself. These are different designs with different fuel requirements. Then come two separate fuel bottlenecks: HALEU is about uranium enrichment. It contains more than 5% but less than 20% uranium-235. Many leading sodium-, helium- and fluoride-salt-cooled designs need it, although not every advanced reactor does. Western production remains limited. Centrus Energy ($LEU) has produced small quantities with demonstration equipment and targets new enrichment capacity in 2029. We do not expect sufficient supply for broad deployment before the late 2020s at the earliest. TRISO is about fuel manufacturing — not a type of coolant. Tiny uranium-bearing particles are wrapped in carbon and ceramic layers designed to retain radioactive fission products even at roughly 1,600°C. That is a major safety advantage, but manufacturing and quality control are demanding. US production already exists, but capacity needs to expand substantially. X-energy’s ( $XE) larger TX-1 facility is still under construction. Helium-cooled and some salt-cooled designs therefore face both bottlenecks: getting HALEU, then turning it into finished TRISO fuel. For investors, a reactor licence is not a fuel supply chain. And a smaller reactor is not automatically a better investment.
@StableBread 1 click

Fajasy on X

Even if the AI model Nubeva Technologies $NBVAF (TSXV: $NBVA) is training to read malware binaries (compiled programs) works, six risks could keep it from paying off: → Labs closing the gap: OpenAI’s GPT-6 Astra nearly doubled GPT-5.6-sol’s score on SRE-Bench, a Columbia University-led test of AI models on reading binaries, within a month of SRE-Bench’s release, and Anthropic says its Claude Mythos Preview model can already reconstruct plausible source code from stripped binaries. The better the labs’ own models get at reading hard binaries, the less they need to pay for outside labels. → Big tech building in-house: Microsoft’s $MSFT Project Ire reverse engineers software files on its own to decide whether they’re malicious. Ire caught only about a quarter of the malware among nearly 4,000 hard-to-classify files in a test Microsoft described in August 2025. But in June 2026, Microsoft said Ire flagged a new malware sample that most major security products, including CrowdStrike’s $CRWD and SentinelOne’s $S, still missed. Google $GOOGL already owns VirusTotal and Mandiant, so the likelier customers are labs that don’t own a malware-scanning site or an incident-response firm already, like OpenAI and Anthropic. → Paid like a contractor: Data labeling companies (firms that turn experts’ knowledge into training data for AI labs) pay 60-70% of what they bill to their contractors, and Scale AI is already recruiting its own malware analysts. So a data labeling company could pay Nubeva by the hour or task, or hire analysts itself, instead of licensing the model or buying the company. → Selling labels teaches the buyer: Every binary Nubeva labels helps the buyer’s model learn the same skill, the reason CEO Randy Chou gave for not patenting how Nubeva reads binaries. So each sale could shrink the edge Nubeva is selling. → Cash and compute: Chou gave no cost for running “hundreds and thousands” of AI agents on a private model. For reference, Nubeva spent $714,772 on R&D in FY2026, equal to 28.7% of its $2.49M in cash as of April 30, 2026. → Missed targets: Nubeva’s AI decryptor builder missed four targets starting in August 2023, so “days and weeks” (Chou’s timeline for the model) is a target, not a result just yet. So even with a working model, Nubeva still has to (1) sign a contract before the labs can read the hardest binaries themselves, (2) get paid for its model and engineers instead of by the hour or task, and (3) fund the training without draining its cash.

Investor Letters

All letters

Capital Wars

CoreWeave’s $35 billion to $39 billion 2026 spending plan relies on debt as unsecured yields reach 15%, making its GPU cloud expansion a…

CRWV $34B
Net Interest 8 clicks

Putting bear cases to rest

Medpace authorized $1 billion of buybacks through 2028 after Q3 revenue rose 8.5% to $716 million; service revenue grew roughly 12% as…

MEDP $18B
Best Anchor Stocks 11 clicks
PYPD · long

Polypid LTD

PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.

PYPD $103M
Value Investors Club

MYR Group q3’26 Earnings Preview

MYR Group’s Q3 2026 preview cites data-center and power transmission demand, with long-term service agreements supporting margin growth and…

MYRG $4B
Monte Independent Investment Research 5 clicks

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 28 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $108M
Triple S Special Situations Investing 4 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 56 of 248

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.